Exploring Drug Discovery and Development through the Lens of AI Technology Enabling Innovation
Moderator: Christopher Locher, PhD, Founder & CEO, Versatope Therapeutics
Sean Ekins, PhD, Founder & CEO, Collaborations Pharmaceuticals
David Harel, MBA, Co-Founder & President, CytoReason
Laura Towart, Founder & CEO, MyPersonalTherapeutics
Jonathan Ward, MBA, Co-Founder & CEO, Genome Biologics
Artificial Intelligence (AI) has had a singular impact on most, if not all, areas of drug discovery and development, from information and understanding the mechanisms of the target disease to finding new biomarkers and creating new data models. AI is enhancing therapeutic innovation through repurposing existing drugs to finding new drug candidates, as well as validating and optimizing drug candidates. This panel will explore advanced applications of AI on drug discovery and development, and what today’s innovation means for tomorrow’s diseases.